Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naive Adults Without Baseline Genotyping Test (D2ARLING Study)

Next Previous
Trial Profile

Efficacy of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naive Adults Without Baseline Genotyping Test (D2ARLING Study)

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Lamivudine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms D2ARLING

Most Recent Events

  • 08 Jul 2025 According to ViiV Healthcare media release, data this study will be presented at the International AIDS Society 2025 Conference (IAS 2025) in Kigali, Rwanda.
  • 07 Nov 2024 According to ViiV Healthcare media release, data from the study will be presented at HIV Glasgow 2024, being held in Glasgow, Scotland from 10 -13 November 2024.
  • 19 Feb 2024 Planned End Date changed from 1 Sep 2023 to 30 Sep 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top